Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections
Open Access
- 9 July 2016
- news
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (14), 6645-6657
- https://doi.org/10.1021/acs.jmedchem.6b00485
Abstract
The clinical management of prosthetic joint infections and other persistent bacterial infections represents a major unmet medical need. The rifamycins are one of the most potent antibiotic classes against persistent bacterial infections, but bacteria can develop resistance to rifamycins rapidly and the clinical utility of the rifamycin class is typically limited to antibiotic combinations to minimize the development of resistance. To develop a better therapy against persistent bacterial infections, a series of rifamycin based bifunctional molecules were designed, synthesized, and evaluated with the goal to identify a dual-acting drug that maintains the potent activity of rifamycins against persistent pathogens and at the same time minimize the development of rifamycin resistance. TNP-2092 was identified as a drug candidate and is currently in an early stage of clinical development for the treatment of prosthetic joint infections.Keywords
This publication has 45 references indexed in Scilit:
- Periprosthetic joint infectionThe Lancet, 2016
- 75% success rate after open debridement, exchange of tibial insert, and antibiotics in knee prosthetic joint infectionsActa Orthopaedica, 2015
- The role of microbial biofilms in prosthetic joint infectionsActa Orthopaedica, 2014
- Biofilms in Periprosthetic Orthopedic InfectionsFuture Microbiology, 2014
- Prosthetic Joint InfectionClinical Microbiology Reviews, 2014
- Antimicrobial treatment concepts for orthopaedic device-related infectionClinical Microbiology & Infection, 2012
- Diagnosis and treatment of implant-associated septic arthritis and osteomyelitisCurrent Infectious Disease Reports, 2008
- Antimycobacterium AgentsPublished by Elsevier BV ,2007
- Therapeutic Opportunities for the Treatment of Biofilm-Associated InfectionsPublished by Elsevier BV ,2004
- History of the Development of RifampinClinical Infectious Diseases, 1983